Sunjay R. Devarajan

Sunjay R. Devarajan

Auto-generated profile, based on publicly available information

Sunjay R. Devarajan

Division of Pulmonology, Department of Medicine Baylor College of Medicine Houston Texas USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2020 in Canadian Journal of Respiratory Therapy
Verified
Journal Article
Open access
ARAniket Rali
Aniket Rali
CHChristopher Howard
Christopher Howard
RMRachel Miller
Rachel Miller
CMChristopher Morgan
Christopher Morgan
DMDennis Mejia
Dennis Mejia
SDSunjay Devarajan
Sunjay Devarajan
Noninvasive positive pressure ventilation (NIPPV) plays an important role in the management of respiratory failure. However, since the emergence of the COVID-19 pandemic, utilization of traditional face mask NIPPV has been curtailed in part due to risk of aerosolization of respiratory particles and subsequent health care worker exposure. A randomized clinical trial in 2016 reported that an alternative interface, helmet NIPPV, may be more effective than traditional NIPPV at preventing intubation and improving mortality. The helmet NIPPV interface provides positive airway pressure, while also theoretically minimizing aerosolization, making it a feasible modality in management of respiratory failure in COVID-19 patients. This report describes a single-center experience of a series of three COVID-19 patients with hypoxemic respiratory failure managed with helmet NIPPV. One patient was able to avoid intubation while a second patient was successfully extubated to NIPPV. Ultimately, the third patient was unable to avoid intubation with helmet NIPPV, although the application of the device was late in the progression of the disease. NIPPV is an important modality in the management of respiratory failure and has been shown to reduce the need for immediate endotracheal intubation in select populations. For patients unable to tolerate facemask NIPPV, the helmet provides an alternate interface. In COVID-19 patients, the helmet interface may reduce the risk of virus exposure to health care workers from aerosolization. Based on this experience, we recommend that helmet NIPPV can be considered as a feasible option for the management of patients with COVID-19, whether the goal is to prevent immediate intubation or avoid post-extubation respiratory failure. Randomized studies are needed to definitively validate the use of helmet NIPPV in this population. Helmet NIPPV is a feasible therapy to manage COVID-19 patients.

1 June 2022 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
AZAndrei Zidaru
Andrei Zidaru
ASAmelia K. Sofjan
Amelia K. Sofjan
SDSunjay R. Devarajan
Sunjay R. Devarajan
VTVincent H. Tam
Vincent H. Tam

1 December 2024 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
SDSunjay R. Devarajan
Sunjay R. Devarajan
KSKristen A. Staggers
Kristen A. Staggers
TWTianshi D. Wu
Tianshi D. Wu
RJRaksha Jain
Raksha Jain

1 March 2021
Verified
Open access
PDF file
SDSunjay R Devarajan
Sunjay R Devarajan
BMBenjamin Musher
Benjamin Musher
JAJames Abraham
James Abraham
Introduction Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause cystic fibrosis (CF), a disease which affects primarily the respiratory and gastrointestinal (GI) tracts. The lifetime risk of colorectal cancer (CRC) in patients with CF is approximately 5-10 times that of the general population. In 2018, the CF Foundation CRC Screening Task Force recommended initiating CRC screening in adults with CF at age 40. Case Presentations In this case series, we present three cases of females with CF younger than age 40 diagnosed with CRC with variable presentations and stages. We discuss the data supporting current CRC screening guidelines in CF in an effort to raise awareness among clinicians regarding young-onset CRC in this population. Furthermore, we aim for this case series to help drive further investigation into the mechanisms underlying CF-related CRC and to open the door to changes in current screening practices. Conclusion People with CF are at substantially higher risk of development of CRC relative to the general population. While current CRC screening practices advocate for earlier screening in this population compared to average-risk patients, this case series highlights potential limitations to current screening guidelines.

28 August 2026 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
DMDanielle Mendonca
Danielle Mendonca
MZMatt S. Zinter
Matt S. Zinter
SDSunjay R. Devarajan
Sunjay R. Devarajan
JBJason Boehme
Jason Boehme
BSBernhard Suter
Bernhard Suter
DPDavut Pehlivan
Davut Pehlivan